Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey

Jakko van Ingen; Stefano Aliberti; Claire Andrejak; James D. Chalmers; Luigi R. Codecasa; Charles L. Daley; Naoki Hasegawa; David E. Griffith; Wouter Hoefsloot; Gwen Huitt; Julie Jarand; Byung Woo Jhun; Michael R. Loebinger; Theodore K. Marras; Kozo Morimoto; Eva Polverino; Felix C. Ringshausen; Miguel Santin; Rachel Thomson; Dirk Wagner; Richard J. Wallace; Kevin L. Winthrop; Jae-Joon Yim

doi:10.1093/cid/ciaa1361

Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey

Jakko van Ingen (Lead / Corresponding author), Stefano Aliberti, Claire Andrejak, James D. Chalmers, Luigi R. Codecasa, Charles L. Daley, Naoki Hasegawa, David E. Griffith, Wouter Hoefsloot, Gwen Huitt, Julie Jarand, Byung Woo Jhun, Michael R. Loebinger, Theodore K. Marras, Kozo Morimoto, Eva Polverino, Felix C. Ringshausen, Miguel Santin, Rachel Thomson, Dirk WagnerRichard J. Wallace, Kevin L. Winthrop, Jae-Joon Yim

Molecular and Clinical Medicine

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

35 Downloads (Pure)

Abstract

Adverse events are frequent in nontuberculous mycobacteria pulmonary disease treatment, but evidence to support their management is scarce. An expert panel survey on management of adverse events shows consistent opinions on management of hepatoxicity, ocular toxicity, ototoxicity, tinnitus, and gastrointestinal upset. These opinions can provide assistance in individual patient management decisions.

Original language	English
Pages (from-to)	e256-e259
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	73
Issue number	1
Early online date	10 Sept 2020
DOIs	https://doi.org/10.1093/cid/ciaa1361
Publication status	Published - 1 Jul 2021

Keywords

Drug-Related Side Effects and Adverse Reactions
Humans
Lung Diseases/chemically induced
Mycobacterium Infections, Nontuberculous
Mycobacterium avium Complex
Mycobacterium avium-intracellulare Infection/drug therapy
Nontuberculous Mycobacteria
Mycobacterium avium complex
antibiotic treatment
nontuberculous mycobacteria
azithromycin
adverse events

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/ciaa1361Licence: CC BY-NC-ND

Final Published VersionFinal published version, 166 KBLicence: CC BY-NC-ND

Cite this

van Ingen, J., Aliberti, S., Andrejak, C., Chalmers, J. D., Codecasa, L. R., Daley, C. L., Hasegawa, N., Griffith, D. E., Hoefsloot, W., Huitt, G., Jarand, J., Jhun, B. W., Loebinger, M. R., Marras, T. K., Morimoto, K., Polverino, E., Ringshausen, F. C., Santin, M., Thomson, R., ... Yim, J-J. (2021). Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey. Clinical Infectious Diseases, 73(1), e256-e259. https://doi.org/10.1093/cid/ciaa1361

@article{0c1de15b3f384f78930bab1047ac4381,

title = "Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey",

abstract = "Adverse events are frequent in nontuberculous mycobacteria pulmonary disease treatment, but evidence to support their management is scarce. An expert panel survey on management of adverse events shows consistent opinions on management of hepatoxicity, ocular toxicity, ototoxicity, tinnitus, and gastrointestinal upset. These opinions can provide assistance in individual patient management decisions.",

keywords = "Drug-Related Side Effects and Adverse Reactions, Humans, Lung Diseases/chemically induced, Mycobacterium Infections, Nontuberculous, Mycobacterium avium Complex, Mycobacterium avium-intracellulare Infection/drug therapy, Nontuberculous Mycobacteria, Mycobacterium avium complex, antibiotic treatment, nontuberculous mycobacteria, azithromycin, adverse events",

author = "{van Ingen}, Jakko and Stefano Aliberti and Claire Andrejak and Chalmers, {James D.} and Codecasa, {Luigi R.} and Daley, {Charles L.} and Naoki Hasegawa and Griffith, {David E.} and Wouter Hoefsloot and Gwen Huitt and Julie Jarand and Jhun, {Byung Woo} and Loebinger, {Michael R.} and Marras, {Theodore K.} and Kozo Morimoto and Eva Polverino and Ringshausen, {Felix C.} and Miguel Santin and Rachel Thomson and Dirk Wagner and Wallace, {Richard J.} and Winthrop, {Kevin L.} and Jae-Joon Yim",

note = "{\textcopyright} The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.",

year = "2021",

month = jul,

day = "1",

doi = "10.1093/cid/ciaa1361",

language = "English",

volume = "73",

pages = "e256--e259",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "1",

}

van Ingen, J, Aliberti, S, Andrejak, C, Chalmers, JD, Codecasa, LR, Daley, CL, Hasegawa, N, Griffith, DE, Hoefsloot, W, Huitt, G, Jarand, J, Jhun, BW, Loebinger, MR, Marras, TK, Morimoto, K, Polverino, E, Ringshausen, FC, Santin, M, Thomson, R, Wagner, D, Wallace, RJ, Winthrop, KL & Yim, J-J 2021, 'Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey', Clinical Infectious Diseases, vol. 73, no. 1, pp. e256-e259. https://doi.org/10.1093/cid/ciaa1361

TY - JOUR

T1 - Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease

T2 - An Expert Panel Survey

AU - van Ingen, Jakko

AU - Aliberti, Stefano

AU - Andrejak, Claire

AU - Chalmers, James D.

AU - Codecasa, Luigi R.

AU - Daley, Charles L.

AU - Hasegawa, Naoki

AU - Griffith, David E.

AU - Hoefsloot, Wouter

AU - Huitt, Gwen

AU - Jarand, Julie

AU - Jhun, Byung Woo

AU - Loebinger, Michael R.

AU - Marras, Theodore K.

AU - Morimoto, Kozo

AU - Polverino, Eva

AU - Ringshausen, Felix C.

AU - Santin, Miguel

AU - Thomson, Rachel

AU - Wagner, Dirk

AU - Wallace, Richard J.

AU - Winthrop, Kevin L.

AU - Yim, Jae-Joon

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Adverse events are frequent in nontuberculous mycobacteria pulmonary disease treatment, but evidence to support their management is scarce. An expert panel survey on management of adverse events shows consistent opinions on management of hepatoxicity, ocular toxicity, ototoxicity, tinnitus, and gastrointestinal upset. These opinions can provide assistance in individual patient management decisions.

AB - Adverse events are frequent in nontuberculous mycobacteria pulmonary disease treatment, but evidence to support their management is scarce. An expert panel survey on management of adverse events shows consistent opinions on management of hepatoxicity, ocular toxicity, ototoxicity, tinnitus, and gastrointestinal upset. These opinions can provide assistance in individual patient management decisions.

KW - Drug-Related Side Effects and Adverse Reactions

KW - Humans

KW - Lung Diseases/chemically induced

KW - Mycobacterium Infections, Nontuberculous

KW - Mycobacterium avium Complex

KW - Mycobacterium avium-intracellulare Infection/drug therapy

KW - Nontuberculous Mycobacteria

KW - Mycobacterium avium complex

KW - antibiotic treatment

KW - nontuberculous mycobacteria

KW - azithromycin

KW - adverse events

UR - http://www.scopus.com/inward/record.url?scp=85111789608&partnerID=8YFLogxK

U2 - 10.1093/cid/ciaa1361

DO - 10.1093/cid/ciaa1361

M3 - Article

C2 - 32910814

SN - 1058-4838

VL - 73

SP - e256-e259

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 1

ER -

Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this